Back to top
more

ImmunoPrecise Antibodies (IPA)

(Delayed Data from NSDQ)

$1.85 USD

1.85
667,297

-0.04 (-2.12%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $1.84 -0.01 (-0.54%) 4:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -100.00% and -17.86%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of 0% and 12.19%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

P3 Health Partners (PIII) delivered earnings and revenue surprises of -88.24% and 3.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nyxoah (NYXH) delivered earnings and revenue surprises of 2% and 40.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Tops Q4 Earnings Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 128.57% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MDxHealth SA (MDXH) delivered earnings and revenue surprises of 30% and 7.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -40% and 12.21%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 13.79% and 0.76%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Patterson Cos. (PDCO) Lags Q2 Earnings Estimates

by Zacks Equity Research

Patterson Cos. (PDCO) delivered earnings and revenue surprises of -4.08% and 2.13%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

IceCure Medical (ICCM) delivered earnings and revenue surprises of -14.29% and 5.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareCloud, Inc. (CCLD) Q3 Earnings Misses Estimates (Revised)

by Zacks Equity Research

CareCloud (CCLD) delivered earnings and revenue surprises of -4.55% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curis (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareCloud, Inc. (CCLD) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

CareCloud (CCLD) delivered earnings and revenue surprises of -4.55% and 0.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -22.22% and 22.44%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 16.22% and 0.35%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies (IPA) delivered earnings and revenue surprises of -420% and 3.29%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 0% and 3.93%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Buy Stocks for February 7th

by Zacks Equity Research

AMSC, META, CLX, IPA and KMPR have been added to the Zacks Rank #1 (Strong Buy) List on February 7, 2023.

Zacks Equity Research

New Strong Buy Stocks for February 5th

by Zacks Equity Research

EZPW, MOD, IPA, WDC and OSK have been added to the Zacks Rank #1 (Strong Buy) List on February 5, 2023.

Zacks Equity Research

Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 19.44% and 2.56%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Buy Stocks for October 23rd

by Zacks Equity Research

MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 35.29% and 7.09%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 1.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?